P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)
JOURNAL OF THORACIC ONCOLOGY（2018）
关键词
Metastatic NSCLC,Biomarkers,Immunotherapy resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要